Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-374-3 | CAS number: 3081-01-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / bone marrow chromosome aberration
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP study, comparable to guideline study with acceptable restriction
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 475 (Mammalian Bone Marrow Chromosome Aberration Test)
- Deviations:
- yes
- Remarks:
- dose levels: only one dose evaluted (no limited test because of signs of toxicicty and death observed below 2000 mg/kg bw), only 50 cells/metaphases analysed per animal
- GLP compliance:
- yes
- Type of assay:
- chromosome aberration assay
Test material
- Reference substance name:
- N-(1,4-dimethylpentyl)-N'-phenylbenzene-1,4-diamine
- EC Number:
- 221-374-3
- EC Name:
- N-(1,4-dimethylpentyl)-N'-phenylbenzene-1,4-diamine
- Cas Number:
- 3081-01-4
- Molecular formula:
- C19H26N2
- IUPAC Name:
- N1-(5-methylhexan-2-yl)-N4-phenylbenzene-1,4-diamine
- Details on test material:
- Santoflex 14
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Duration of treatment / exposure:
- sampling time: 6 h, 18 h and 30 h
- Frequency of treatment:
- once
- Post exposure period:
- sampling time: 6 h, 18 h and 30 h
Doses / concentrations
- Dose / conc.:
- 1 100 mg/kg bw/day (nominal)
- Remarks:
- (given as "mg/kg bw")
- No. of animals per sex per dose:
- 10 per dose and sampling time (5 males and 5 females)
- Control animals:
- yes
Examinations
- Tissues and cell types examined:
- bone marrow cells from both femurs
- Statistics:
- Mean aberrations per cell per rat (50 cells per rat) were analyzed for statistically significant increases in chromosome aberration by one-tailed t tests. Each treatment group was analyzed separately as compared to its concurrent negative control group. The mean and standard deviation of aberrations/cell were also determined for each group of rats (500 cells; 50 cells per rat). The number of aberrant metaphases was analyzed by Chi¿square analysis for statistically significant increases. Statistical significance was determined at the p 0.05 probability level.
Results and discussion
Test results
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- yes
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
Any other information on results incl. tables
Dose range finding study:
In the dose range finding study, SANTOFLEX 14 was dosed at 1.14 mL/kg (1050 mg/kg) as received. Rats dosed with SANTOFLEX 14 did not exhibit any pharmacotoxic signs until day three. On Day 3 and 7, the animals exhibited moderate pharinacotoxic signs. At the sponsors request, two other groups of rats were dosed with higher volumes: 1.63 mL/kg (1500 mg/kg) and 2.17 mL/kg (2000 mg/kg) of SANTOFLEX 14 with the last dose being near the LD50 (2100 mg/kg). Both females dosed at 2.17 mL/kg (2000 mg/kg) died by Day 3 and both males by Day 4. Both females dosed at 1.63 mL/kg (1500 mg/kg) also were dead by Day 3. The males exhibited severe pharmacotoxic signs through Day 6 when sacrificed at the sponsors request.
Based on these results, two other groups of rats were dosed with lower volumes of 1.30 mL/kg (1200 mg/kg) and 1.2 mL/kg (1100 mg/kg). Both groups of rats exhibited from moderate to severe pharinacotoxic signs. Several females of these dose groups lost approximately 12-14 grams of body weight by the Day 2 observation. However, the males had minimum weight loss of (4-7 grams) by the Day 2 observation.
Based on these findings and with the sponsors approval, a dose level of 1100 mg/kg was chosen as the dose for evaluation in the metaphase analysis, as an estimate of the maximum tolerated dose.
Main experiment:
Clinical signs:
During the In Vivo phase of the assay, rats were observed for pharmacotoxic effects in the metaphase assay immediately after dosing and again just prior to coichicine administration.
No pharmacotoxic signs were observed in animals administered SANTOFLEX 14 immediately after dosing. Pharmacotoxic signs observed prior to colchicine administration in all groups treated with SANTOFLEX 14 were as follows:
6 Hour Group - (observed approximately 4 hours after dosing): All males had decreased body tone and piloerection. All females had decreased body tone and vocalization on touch. In addition, two females had arched back and abnormal stance.
18 Hour Group - (observed approximately 16 hours after dosing): Two males had decreased body tone. One male had vocalization when touched, abnormal stance and arched back. Another male had piloerection and diarrhea. The other two males had no apparent pharmacotoxic signs. All females had decreased body tone with four females exhibiting piloerection and abnormal stance. Two females made vocalizations when touched. One female had also arched back.
30 Hour Group - (observed approximately 28 hours after dosing): All rats had decreased body tone and piloerection. Three males and two females made vocalizations when touched. One male and one female had an arched back. In addition, one female had abnormal gait.
These observations suggested that the rats dosed with Santoflex 14 at 1100 mg/kg exhibited moderate to severe pharmacotoxic signs indicating that these animals were dosed at or near the maximum tolerated dose.One of the males in the positive control group exhibited decreased body tone.No pharmacotoxic signs were observed in the other rats administered the vehicle or the positive controls.
Metaphase analysis:
Proportion of Cells with Aberrations:
The proportion of cells with one or more aberrations was analyzed by Chi-square analysis, by comparing the proportion of cells with aberrations in each treatment group versus the negative control. Each time of sacrifice was analyzed separately and groups within each sacrifice time were compared individually to the negative control. Cells with gaps only were not considered aberrant for this analysis. A statistically significant increase (p 0.01) was detected with the positive control CP group at the 18 hour sacrifice. In addition, four metaphases with multiple aberrations were found in the positive control CP group. These unscorable metaphases were not included in the 100 metaphases analyzed for statistical significance. These metaphases comprised 3.85 % of the total aberrant metaphases found in that group. No other significant differences were noted.
Analysis of Aberrations per Cell:
The mean number of aberrations per cell per animal was analyzed for statistically significant increases by one-tailed t-tests for each time interval. Data reflect the total number of aberrations seen in all cells scored per group. No statistically significant increases (p 0.05) from the negative controls were detected by this analysis in animals treated with SANTOFLEX 14.
CONCLUS ION
Statistical analyses of the data indicated that SANTOFLEX 14 (1100 mg/kg) did not produce significant increases in the number of aberrations or in the number of aberrant metaphases at any of the three sacrifice times evaluated. Pharmacotoxic signs observed during the study indicated that Santoflex 14 was dosed near the maximum tolerated dose. Therefore, SANTOFLEX 14 was judged negative in its ability to induce structural chromosomal aberrations to the hemopoietic cells of the rat bone marrow under the experimental conditions of this assay.
Proportion of cells with one or more aberrations
Compound | dose (mg/kg) | Harvest time (h) | No. of cells with one or more aberration(500 cells) | Mean proportionof aberrant cells per animal +/- SD | % aberrant cells per group |
negative control | 0 | 6 | 2 | 0.004 ± 0.008 | 0.4 |
Santoflex 14 | 1100 | 6 | 2 | 0.004 ± 0.008 | 0.4 |
negative control | 0 | 18 | 6 | 0.012 ± 0.014 | 1.2 |
Santoflex 14 | 1100 | 18 | 6 | 0.012 ± 0.019 | 1.2 |
CP (positive control) | 20 | 18 | 251 | 0.502 ± 0.04** | 50.2 |
negative control | 0 | 30 | 1 | 0.002 ± 0.006 | 0.2 |
Santoflex 14 | 1100 | 30 | 5 | 0.01 ± 0.014 | 1.0 |
** significant different from negative control (p<0.01)
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.